NCT04516720 Creation of a Clinical Database on Primary Nervous System Tumors
| NCT ID | NCT04516720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Condition | Nervous System Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,700 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2035-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,700 participants in total. It began in 2018-01-01 with a primary completion date of 2035-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
the creation of a clinical database including data for all PCNST patients is of high interest. This database will allow us to develop clinical studies on: * The clinical, radiological and biological presentation of tumors, the impact of oncological treatments and the evaluation of survival for the different subtypes of Primary central nervous system tumors (PCNST). This is particularly important for rare histological subtypes of PCNST for which the current knowledge is scarce; * Clinical, radiological and biological factors predictive of tumor response to treatments; * Prognostic factors.
Eligibility Criteria
Inclusion Criteria: * Adult patient aged ≥ 18, no age limit; * Diagnosis of Primary central nervous system tumors ; * Patient treated at the Montpellier Cancer Institute, whatever the treatment received (systemic treatment, radiotherapy or exclusive supportive care); * For the retrospective part of the study, patient first treated at the Montpellier Cancer Institute between January 1rst, 2004 and the beginning of the prospective part; * Patient information for the retrospective (patient still alive at the beginning of the study) and prospective study. Exclusion Criteria: * Secondary lesions of the central nervous system; * Patient not affiliated to a social protection scheme; * Subject under tutelage, curatorship or safeguard of justice.
Contact & Investigator
Amélie DARLIX, MD
STUDY CHAIR
Institut régional du Cancer Montpellier
Frequently Asked Questions
Who can join the NCT04516720 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nervous System Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04516720 currently recruiting?
Yes, NCT04516720 is actively recruiting participants. Contact the research team at DRCI-icm105@icm.unicancer.fr for enrollment information.
Where is the NCT04516720 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT04516720 clinical trial?
NCT04516720 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is Amélie DARLIX, MD at Institut régional du Cancer Montpellier. The trial plans to enroll 1,700 participants.